In 2015, we led the way in investment and licensing support for University spin-out Fluidic Analytics.
Fluidic Analytics secured a licence from Cambridge Enterprise, as well as £1.56 million from our Seed Funds and other investors, to develop tools to identify the ‘protein fingerprints’ of disease. Fluidic Analytics’ cutting-edge bioscience technology is based on research conducted by Professor Tuomas Knowles, of the Department of Chemistry.
In contrast to the use of DNA, whose sequence provides information on the likelihood of developing a disease at some point in life, proteins provide real-time information on the actual disease state of the body. Current information on disease is widely seen as the key to timely, effective medical treatment.Tags: disease, DNA, fluidic analytics, proteins, tuomas knowles